This program would give us step by step financial support (total double digit million dollars expected) from preclinical to human proof of concept studies. UI-102 is a potential best in class systemic immune modulator leveraging our Myeloid Targeting PlatformTM to treat patients suffering from cold tumors. We are thankful for all of our supporters.
Read more (Japanese)